Literature DB >> 15372475

Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.

Christer Lindholm1, Ronny Andersson, Monika Dufmats, Johan Hansson, Christian Ingvar, Torgil Möller, Helena Sjödin, Ulrika Stierner, Gunnar Wagenius.   

Abstract

BACKGROUND: The objective of the current study was to compile prospective, population-based data on cutaneous invasive melanomas in Sweden during the period from 1990 to 1999, to describe and analyze survival data and prognostic factors, and to make comparisons with previously published Swedish and international data.
METHODS: Twelve thousand five hundred thirty-three patients, which included 97% of all registered melanomas in Sweden, were included and described. Among these, 9515 patients with clinical Stage I and II melanoma were included in an analysis of survival and in a univariate analysis, and 6191 patients were included in a multivariate analysis of prognostic factors.
RESULTS: There was no significant change in melanoma incidence during 1990-1999. Favorable prognostic factors were found, especially in younger and female patients, resulting in a relative 5-year survival rate of 91.5%. In the multivariate analysis, significant factors that had a negative effect on survival were Clark level of invasion, Breslow thickness, ulceration, older patient age, trunk location, greatest tumor dimension, nodular histogenetic type, and male gender.
CONCLUSIONS: During the period from 1990 to 1999, the 5-year survival of patients with malignant melanoma in Sweden was better compared with the previously reported rates in published, population-based studies from Sweden, probably as a result of better secondary prevention due to better knowledge and awareness by both patients and the medical profession. The more favorable prognostic factors and the change in melanoma location found in younger patients, compared with earlier reports, may reflect changes in clothing as well as tanning habits; however, a decrease also was found in Clark Level II and thin melanomas for the same patient group. The authors concluded that further improvements can be achieved with better access to health care and with the use of early melanoma detection campaigns.

Entities:  

Mesh:

Year:  2004        PMID: 15372475     DOI: 10.1002/cncr.20602

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Construction and analysis of multiparameter prognostic models for melanoma outcome.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  Methods Mol Biol       Date:  2014

Review 2.  Epidemiology and prevention of cutaneous melanoma.

Authors:  Marie-France Demierre
Journal:  Curr Treat Options Oncol       Date:  2006-05

3.  Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation.

Authors:  Thomas J Hornyak; Shunlin Jiang; Esther A Guzmán; Beth N Scissors; Chinisada Tuchinda; Hongbin He; James D Neville; Faith M Strickland
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-03       Impact factor: 4.693

4.  Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study.

Authors:  Anne Kricker; Bruce K Armstrong; Chris Goumas; Nancy E Thomas; Lynn From; Klaus Busam; Peter A Kanetsky; Richard P Gallagher; Loraine D Marrett; Pamela A Groben; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Terence Dwyer; Marianne Berwick
Journal:  JAMA Dermatol       Date:  2013-08       Impact factor: 10.282

5.  High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Authors:  Björn Nodin; Marie Fridberg; Liv Jonsson; Julia Bergman; Mathias Uhlén; Karin Jirström
Journal:  Diagn Pathol       Date:  2012-07-17       Impact factor: 2.644

6.  Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study.

Authors:  Marie Fridberg; Liv Jonsson; Julia Bergman; Björn Nodin; Karin Jirström
Journal:  Biol Sex Differ       Date:  2012-07-02       Impact factor: 5.027

7.  Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Authors:  Liv Jonsson; Julia Bergman; Björn Nodin; Jonas Manjer; Fredrik Pontén; Mathias Uhlén; Karin Jirström
Journal:  J Transl Med       Date:  2011-07-21       Impact factor: 5.531

8.  Incidence and mortality trends of melanoma in Croatia.

Authors:  Jelena Barbarić; Ariana Znaor
Journal:  Croat Med J       Date:  2012-04       Impact factor: 1.351

Review 9.  A roadmap for the clinical implementation of optical-imaging biomarkers.

Authors:  Dale J Waterhouse; Catherine R M Fitzpatrick; Brian W Pogue; James P B O'Connor; Sarah E Bohndiek
Journal:  Nat Biomed Eng       Date:  2019-04-29       Impact factor: 29.234

Review 10.  Epidemiology of invasive cutaneous melanoma.

Authors:  R M MacKie; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.